Results 31 to 40 of about 58,205 (308)
Hematology, 2023 Objective IDH1/2 mutations, intervening in epigenetic procedures, are frequently encountered in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Vasiliki Papadopoulou +6 more
doaj +1 more source
TET2 inhibits differentiation of embryonic stem cells but does not overcome methylation-induced gene silencing [PDF]
, 2014 TET2 is a methylcytosine dioxygenase that is frequently mutated in myeloid malignancies, notably myelodysplasia and acute myeloid leukemia. TET2 catalyses the conversion of 5′-methylcytosine to 5′-hydroxymethylcytosine within DNA and has been implicated ...
Chevassut, Timothy +2 more
core +3 more sources
Molecular and Genetic Determinants of Glioma Cell Invasion. [PDF]
, 2017 A diffusely invasive nature is a major obstacle in treating a malignant brain tumor, "diffuse glioma", which prevents neurooncologists from surgically removing the tumor cells even in combination with chemotherapy and radiation.
Kato, Yoichiro +4 more
core +2 more sources
Future Science OA, 2021 Aim: The implications of molecular biomarkers IDH1/2 mutations and MGMT gene promoter methylation were evaluated for prognostic outcome of glioma patients. Materials & methods: Glioma cases were analyzed for IDH1/2 mutations and MGMT promoter methylation
Arshad A Pandith +13 more
doaj +1 more source
Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients [PDF]
, 2019 Methylation of the O(6)-Methylguanine-DNA methyltransferase (MGMT) promoter is predictive for treatment response in glioblastoma patients. However, precise predictive cutoff values to distinguish "MGMT methylated" from "MGMT unmethylated" patients remain
Hempt, Claudia +12 more
core +1 more source
The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET
BMC Cancer, 2021 Background Non-invasive diagnosis of IDH1 mutation for gliomas has great clinical significance, and PET has natural advantage to detect metabolism, as IDH mutated gliomas share lower glucose consumption. Methods Clinical data of patients with gliomas and
Feng-Min Liu +9 more
doaj +1 more source
IDH1 Non-Canonical Mutations and Survival in Patients with Glioma
Diagnostics, 2021 Background: Non-canonical mutations of the isocitrate dehydrogenase (IDH) genes have been described in about 20–25% and 5–12% of patients with WHO grade II and III gliomas, respectively.
Enrico Franceschi +10 more
doaj +1 more source
NIMG-42LOWER BRAIN NETWORK EFFICIENCY IN IDH1 WILD TYPE (IDH-WT) MALIGNANT ASTROCYTOMA COMPARED TO IDH1 MUTANT (IDH1-M) [PDF]
Neuro-Oncology, 2015 We previously demonstrated that patients with IDH1-WT compared to IDH1-M malignant astrocytoma exhibited worse cognitive function. We hypothesized that this is due to greater lesion momentum that may preclude compensatory brain reorganization. Therefore, in the present study, we examined the structural connectome of patients with IDH1-M and -WT tumors ...
Shelli Kesler +4 more
openaire +1 more source
Turkish Journal of Hematology, 2017 We aimed to determine the genotype distribution, allele frequency, and prognostic impact of IDH1/2, TET2, and ASXL1 single nucleotide polymorphisms (SNPs) in myeloproliferative neoplasms (MPNs).
Nur Soyer +7 more
doaj +1 more source
Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. [PDF]
, 2019 Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML).
Chan, Steven M +4 more
core +1 more source